Dishman Carbogen Amcis Limited (BOM:540701)

Market Cap	27.21B -36.2%
Revenue (ttm)	29.01B -0.0%
Net Income	161.60M -84.5%
EPS	1.03 -84.7%
Shares Out	n/a
PE Ratio	168.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,950
Open	173.40
Previous Close	171.85
Day's Range	172.55 - 181.95
52-Week Range	129.00 - 321.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 1,106
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540701

Financial Performance

In fiscal year 2026, Dishman Carbogen Amcis's revenue was 29.32 billion, an increase of 8.13% compared to the previous year's 27.12 billion. Earnings were 974.50 million, an increase of 2907.72%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error